title: Prognostic significance of CD100 expression in soft tissue sarcoma.
abstract: BACKGROUND
  CD100, a class IV semaphorin, promotes angiogenesis, invasive growth, proliferation, and antiapoptosis of cancer cells in vitro. The expression of CD100 in soft tissue sarcoma (STS) and its correlation with clinicopathologic factors and prognostic significance were evaluated.
  
  
  METHODS
  Expression levels of CD100 in patients with localized STS were evaluated immunohistochemically on paraffin-embedded sections from 81 patients, including 47 men and 34 women with a median age of 54 years. Staining intensity was categorized into weaker than (level 1) or equal to that of lymphocytes with a rate of <10% stained tumor cells (level 2) or >10% stained tumor cells (level 3). Ki-67 staining was performed in parallel.
  
  
  RESULTS
  Forty-two tumors (52%) had level 1 CD100 expression, 18 tumors (22%) had level 2 CD100 expression, and 21 tumors (26%) had level 3 CD100 expression. Tumors that had level 2 and 3 CD100 expression were correlated significantly with higher mitotic count, cellularity, ratio of necrosis, and Ki-67 labeling index (LI) compared with tumors that had level 1 CD100 expression. There was no correlation between CD100 expression and other characteristics. Among the 3 levels of CD100 expression, higher expression levels were correlated with poorer overall and disease-free survival. Multivariate analysis revealed that CD100 expression (levels 1 and 2 vs level 3) and tumor size (<or=5 cm vs >5 cm) were independent prognosticators for overall survival (P < .05 for both), and CD100 expression (levels 1 and 2 vs level 3) was an independent prognosticator for disease-free survival (P < .05).
  
  
  CONCLUSIONS
  The results from this study indicated the demonstrated prognostic significance of CD100 expression in STS.
authors.affiliation: Department of Pathology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
authors.forename: Eweseng
authors.initials: E
authors.lastname: Ch'ng
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Tomita
authors.forename: Binglin
authors.initials: B
authors.lastname: Zhang
authors.forename: Juxiang
authors.initials: J
authors.lastname: He
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Hoshida
authors.forename: Ying
authors.initials: Y
authors.lastname: Qiu
authors.forename: Eiichi
authors.initials: E
authors.lastname: Morii
authors.forename: Itsuko
authors.initials: I
authors.lastname: Nakamichi
authors.forename: Ken-ichiro
authors.initials: K
authors.lastname: Hamada
authors.forename: Takafumi
authors.initials: T
authors.lastname: Ueda
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Aozasa
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000096:biosynthesis*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000032:analysis; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D012509:Sarcoma / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D039961:Semaphorins / Q000096:biosynthesis*; D016019:Survival Analysis; D047368:Tumor Burden
chemical_list: D015703:Antigens, CD; C093224:CD100 antigen; D019394:Ki-67 Antigen; D039961:Semaphorins